BioCentury
ARTICLE | Clinical News

ApoGraft: Ph I/II started

February 9, 2017 9:56 PM UTC

Cellect began an open-label, Israeli Phase I/II trial to evaluate transplanted ApoGraft exposed to 10, 25, 50 or 100 ng/mL FASL in about 12 patients undergoing allogeneic stem cell transplantation (AS...

BCIQ Company Profiles

Cellect Biotechnology Ltd.